FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087016166> ?p ?o ?g. }

• W3087016166 endingPage "e22043" @default.
• W3087016166 startingPage "e22043" @default.
• W3087016166 abstract "Atopic dermatitis (AD) is a common eczematous skin disorder that profoundly reduces the quality of life due to intractable pruritus. Excellent therapeutic success of the anti-interleukin 4 receptor-α antibody dupilumab in clinical trials and a real-world clinical context indicates the crucial roles of interleukin (IL)-4 and IL-13 in the pathogenesis of AD. Along with the clinical improvement in skin scores and pruritus, dupilumab significantly and progressively reduces and normalizes the upregulated expression of T helper type 2 signatures such as Chemokine (C-C motif) ligand (CCL)17, CCL18, CCL22, and CCL26 in the lesional skin of AD. However, no blood/serum biomarkers are known to predict good or poor outcome in patients with AD treated with dupilumab.Patients are at least 18 years of age and have moderate-to-severe AD with Eczema Area and Severity Index (EASI) ≥16, Investigator's Global Assessment ≥3, and body surface area ≥10%. We are going to enroll more than 130 subjects from 18 medical facilities. Clinical objective findings will be evaluated by EASI. Subjective symptoms will be assessed by Patient-Oriented Eczema Measure, Numerical Rating Scale for Pruritus (Pruritus-NRS), Skin Comfort-NRS, and Treatment Satisfaction-NRS. We will measure 18 blood/serum biomarkers including % eosinophils in blood cell count, lactate dehydrogenase, total IgE, soluble interleukin 2 receptor, CCL17, CCL18, CCL22, CCL26, CCL27, IL-13, IL-22, IL-24, IL-25, IL-31, IL-33, thymic stromal lymphopoietin, periostin, and squamous cell carcinoma antigen-2. The clinical evaluation and biomarker sampling will be performed at 0, 2, 4, 8, and 16 weeks of dupilumab treatment. We will also perform proteomic analysis (of roughly 300 proteins) of the patients' sera obtained at 0 and 2 weeks of treatment. The primary endpoint is the association between baseline levels of 18 biomarkers and % change from baseline of EASI at 16 weeks of dupilumab treatment.This is the first clinical trial to explore the biomarkers, including potential proteomic markers, most strongly associated with improvement in EASI in patients with moderate-to-severe AD treated with dupilumab for 16 weeks (B-PAD study). A limitation is that we will only enroll Japanese patients." @default.
• W3087016166 created "2020-09-25" @default.
• W3087016166 creator A5001863012 @default.
• W3087016166 creator A5002306119 @default.
• W3087016166 creator A5006129456 @default.
• W3087016166 creator A5012182744 @default.
• W3087016166 creator A5012591005 @default.
• W3087016166 creator A5014643091 @default.
• W3087016166 creator A5014750615 @default.
• W3087016166 creator A5015950702 @default.
• W3087016166 creator A5016106271 @default.
• W3087016166 creator A5021131852 @default.
• W3087016166 creator A5021306940 @default.
• W3087016166 creator A5024531277 @default.
• W3087016166 creator A5027554519 @default.
• W3087016166 creator A5030364184 @default.
• W3087016166 creator A5031575826 @default.
• W3087016166 creator A5032233192 @default.
• W3087016166 creator A5035130687 @default.
• W3087016166 creator A5037317056 @default.
• W3087016166 creator A5037599908 @default.
• W3087016166 creator A5038650320 @default.
• W3087016166 creator A5043225877 @default.
• W3087016166 creator A5047135535 @default.
• W3087016166 creator A5048960816 @default.
• W3087016166 creator A5051113472 @default.
• W3087016166 creator A5055239026 @default.
• W3087016166 creator A5057230322 @default.
• W3087016166 creator A5067850118 @default.
• W3087016166 creator A5067909005 @default.
• W3087016166 creator A5068045003 @default.
• W3087016166 creator A5068882550 @default.
• W3087016166 creator A5069284241 @default.
• W3087016166 creator A5072474288 @default.
• W3087016166 creator A5072779683 @default.
• W3087016166 creator A5073117349 @default.
• W3087016166 creator A5073596380 @default.
• W3087016166 creator A5079729964 @default.
• W3087016166 creator A5080884788 @default.
• W3087016166 creator A5081523770 @default.
• W3087016166 creator A5082909666 @default.
• W3087016166 creator A5083485606 @default.
• W3087016166 creator A5087617455 @default.
• W3087016166 creator A5089539362 @default.
• W3087016166 date "2020-09-18" @default.
• W3087016166 modified "2023-09-27" @default.
• W3087016166 title "Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab" @default.
• W3087016166 cites W1506450640 @default.
• W3087016166 cites W1527957830 @default.
• W3087016166 cites W1964820219 @default.
• W3087016166 cites W1980040943 @default.
• W3087016166 cites W1983822796 @default.
• W3087016166 cites W1999387064 @default.
• W3087016166 cites W2002600662 @default.
• W3087016166 cites W2003774999 @default.
• W3087016166 cites W2012868073 @default.
• W3087016166 cites W2015136829 @default.
• W3087016166 cites W2017850486 @default.
• W3087016166 cites W2029005903 @default.
• W3087016166 cites W2080176520 @default.
• W3087016166 cites W2091063875 @default.
• W3087016166 cites W2095569485 @default.
• W3087016166 cites W2104004846 @default.
• W3087016166 cites W2117359358 @default.
• W3087016166 cites W2127482775 @default.
• W3087016166 cites W2138355864 @default.
• W3087016166 cites W2166917684 @default.
• W3087016166 cites W2169177355 @default.
• W3087016166 cites W2171578277 @default.
• W3087016166 cites W2337446585 @default.
• W3087016166 cites W2342693354 @default.
• W3087016166 cites W2346851822 @default.
• W3087016166 cites W2407647427 @default.
• W3087016166 cites W2411361269 @default.
• W3087016166 cites W2470735313 @default.
• W3087016166 cites W2511120040 @default.
• W3087016166 cites W2524051065 @default.
• W3087016166 cites W2568590455 @default.
• W3087016166 cites W2593200577 @default.
• W3087016166 cites W2605967522 @default.
• W3087016166 cites W2732263256 @default.
• W3087016166 cites W2752670171 @default.
• W3087016166 cites W2770276039 @default.
• W3087016166 cites W2786823650 @default.
• W3087016166 cites W2791135802 @default.
• W3087016166 cites W2791157899 @default.
• W3087016166 cites W2792202538 @default.
• W3087016166 cites W2802952796 @default.
• W3087016166 cites W2810820884 @default.
• W3087016166 cites W2883397252 @default.
• W3087016166 cites W2892288216 @default.
• W3087016166 cites W2903947057 @default.
• W3087016166 cites W2908925106 @default.
• W3087016166 cites W2914291047 @default.
• W3087016166 cites W2914603675 @default.
• W3087016166 cites W2949571623 @default.
• W3087016166 cites W2963933526 @default.
• W3087016166 cites W2979421310 @default.

• next